Subscribe: pubmed: Blood Reviews [Jour]
http://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=0AdWssYm5a7GW6jJuaYIan2USBcvx95w25nA0ycurLW
Preview: pubmed: Blood Reviews [Jour]

pubmed: Blood Reviews [Jour]



NCBI: db=pubmed; Term="Blood Reviews"[Jour]



 



Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era.
Related Articles

Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era.

Blood Rev. 2017 May 03;:

Authors: Butler LA, Tam CS, Seymour JF

Abstract
The anti-CD20 antibodies represent a major advancement in the therapeutic options available for chronic lymphocytic leukemia. The addition of rituximab, ofatumumab and obinutuzumab to various chemotherapy regimens has led to considerable improvements in both response and survival. Ocaratuzumab, veltuzumab and ublituximab are currently being explored within the trial setting. We review the current status of these antibodies, and discuss how their mechanisms of action may impact on the choice of combinations with novel small molecule agents.

PMID: 28499646 [PubMed - as supplied by publisher]